IMM 1.56% 31.5¢ immutep limited

cure for foot and mouth?, page-2

  1. 345 Posts.
    Prr seem to have been developing nicely and although a biased opinion managemnet claims that the value of their intellectual property far exceeds the current share price.
    Their portfolio of research projects focus on the following areas:
    -technology that has the potential to both prevent and treat Malaria
    -development of tumour antigens to target cancer cells of the breast, lungs, colon, ovaries and prostate
    -development of new drugs for rheumatoid athritis
    -producing an immune response in large animals leading to a vaccination against foot and mouth disease.
    Several licences and royalties in the pipeline with significant announcements due in July. Worth a punt at current levels, who knows how this one may run if any one of their technologies is a hit.
 
watchlist Created with Sketch. Add IMM (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.